- Home
- MKTX vs RGEN Comparison
MKTX vs RGEN Comparison
Compare MKTX & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTX
- RGEN
- Stock Information
- Founded
- MKTX 2000
- RGEN 1981
- Country
- MKTX United States
- RGEN United States
- Employees
- MKTX N/A
- RGEN N/A
- Industry
- MKTX Investment Bankers/Brokers/Service
- RGEN Medical/Dental Instruments
- Sector
- MKTX Finance
- RGEN Health Care
- Exchange
- MKTX Nasdaq
- RGEN Nasdaq
- Market Cap
- MKTX 8.1B
- RGEN 8.0B
- IPO Year
- MKTX 2004
- RGEN N/A
- Fundamental
- Price
- MKTX $213.13
- RGEN $131.55
- Analyst Decision
- MKTX Buy
- RGEN Buy
- Analyst Count
- MKTX 9
- RGEN 12
- Target Price
- MKTX $241.78
- RGEN $172.67
- AVG Volume (30 Days)
- MKTX 498.9K
- RGEN 847.4K
- Earning Date
- MKTX 05-07-2025
- RGEN 04-29-2025
- Dividend Yield
- MKTX 1.43%
- RGEN N/A
- EPS Growth
- MKTX N/A
- RGEN N/A
- EPS
- MKTX 5.76
- RGEN N/A
- Revenue
- MKTX $815,355,000.00
- RGEN $650,429,000.00
- Revenue This Year
- MKTX $7.50
- RGEN $13.93
- Revenue Next Year
- MKTX $10.21
- RGEN $14.35
- P/E Ratio
- MKTX $36.97
- RGEN N/A
- Revenue Growth
- MKTX 7.33
- RGEN 4.88
- 52 Week Low
- MKTX $186.84
- RGEN $102.97
- 52 Week High
- MKTX $296.68
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- MKTX 41.25
- RGEN 47.85
- Support Level
- MKTX $218.00
- RGEN $123.10
- Resistance Level
- MKTX $232.84
- RGEN $143.56
- Average True Range (ATR)
- MKTX 6.33
- RGEN 6.82
- MACD
- MKTX -1.07
- RGEN -0.65
- Stochastic Oscillator
- MKTX 7.03
- RGEN 33.43
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.